Skip to content

Annexon ANNX Free cash flow

Free cash flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$28.87M-4.4%
Omeros logo
OmerosOMER
-$14.51M+59.6%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$25.94M-142%

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's free cash flow?
Annexon (ANNX) reported free cash flow of -$46.8M in Q1 2026.
How has Annexon's free cash flow changed year-over-year?
Annexon's free cash flow increased by 6.6% year-over-year, from -$50.13M to -$46.8M.
What is the long-term trend for Annexon's free cash flow?
Over 3 years (2021 to 2025), Annexon's free cash flow has grown at a 20.1% compound annual growth rate (CAGR), from -$107.76M to -$186.49M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.